Your browser doesn't support javascript.
loading
Using circulating O-sulfotyrosine in the differential diagnosis of acute kidney injury and chronic kidney disease.
Chen, Shuai; Liu, Yong-Hua; Dai, Dao-Peng; Zhu, Zheng-Bin; Dai, Yang; Wu, Zhi-Ming; Zhang, Li-Ping; Duan, Zhi-Feng; Lu, Lin; Ding, Feng-Hua; Zhu, Jin-Zhou; Zhang, Rui-Yan.
Affiliation
  • Chen S; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Liu YH; Department of Cardiology, Bao Shan People's Hospital, Baoshan, Yunnan Province, China.
  • Dai DP; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhu ZB; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Dai Y; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wu ZM; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhang LP; Department of Cardiology, Bao Shan People's Hospital, Baoshan, Yunnan Province, China.
  • Duan ZF; Department of Cardiology, Bao Shan People's Hospital, Baoshan, Yunnan Province, China.
  • Lu L; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ding FH; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ruijindfh@126.com.
  • Zhu JZ; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. holmsfred@163.com.
  • Zhang RY; Department of Vascular & Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhangruiyan@263.net.
BMC Nephrol ; 22(1): 66, 2021 02 23.
Article de En | MEDLINE | ID: mdl-33622294
BACKGROUND: Sulfation of tyrosine, yielding O-sulfotyrosine, is a common but fixed post-translational modification in eukaryotes. Patients with increased circulating O-sulfotyrosine levels experience a faster decline in renal function with progression to end-stage renal disease (ESRD). In the present study, we measured serum O-sulfotyrosine levels in individuals with chronic kidney disease (CKD) and acute kidney injury (AKI) to explore its ability to differentiate AKI from CKD. METHODS: A total of 135 patients (20 with AKI and 115 with CKD) were recruited prospectively for liquid chromatography-mass spectrometry assessment of circulating O-sulfotyrosine. We also studied C57BL/6 mice with CKD after 5/6 nephrectomy (Nx). Blood samples were drawn from the tail vein on Day 1, 3, 5, 7, 14, 30, 60, and 90 after CKD. Serum separation and characterization of creatinine, blood urea nitrogen (BUN), and O-sulfotyrosine was performed. Thus, the time-concentration curves of the O-sulfotyrosine level demonstrate the variation of kidney dysfunction. RESULTS: The serum levels of O-sulfotyrosine were markedly increased in patients with CKD compared with AKI. Median O-sulfotyrosine levels in CKD patients versus AKI, respectively, were as follows:243.61 ng/mL(interquartile range [IQR] = 171.90-553.86) versus 126.55 ng/mL (IQR = 48.19-185.03, P = 0.004). In patients with CKD, O-sulfotyrosine levels were positively correlated with creatinine, BUN, and Cystatin C (r = 0.63, P < 0.001; r = 0.49, P < 0.001; r = 0.61, P < 0.001, respectively) by the multivariate linear regression analysis (ß = 0.71, P < 0.001; ß = 0.40, P = 0.002; ß = 0.73, P < 0.001, respectively). However, this association was not statistically significant in patients with AKI (r = - 0.17, P = 0.472; r = 0.11, P = 0.655; r = 0.09, P = 0.716, respectively). The receiver operating characteristic (ROC) analysis illustrated that the area under the curve was 0.80 (95% confidence interval [CI] 0.71-0.89; P < 0.001) and the optimal cut-off value of serum O-sulfotyrosine suggesting AKI was < 147.40 ng/mL with a sensitivity and specificity of 80.90 and 70.00% respectively. In animal experiments, serum levels of O-sulfotyrosine in mice were elevated on Day 7 after 5/6 nephrectomy (14.89 ± 1.05 vs. 8.88 ± 2.62 ng/mL, P < 0.001) until Day 90 (32.65 ± 5.59 vs. 8.88 ± 2.62 ng/mL, P < 0.001). CONCLUSION: Serum O-sulfotyrosine levels were observed correlated with degrading renal function and in CKD patients substantially higher than those in AKI patients. Thus serum O-sulfotyrosine facilitated the differential diagnosis of AKI from CKD.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tyrosine / Insuffisance rénale chronique / Atteinte rénale aigüe Type d'étude: Diagnostic_studies / Prognostic_studies Limites: Aged / Animals / Female / Humans / Male / Middle aged Langue: En Journal: BMC Nephrol Sujet du journal: NEFROLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tyrosine / Insuffisance rénale chronique / Atteinte rénale aigüe Type d'étude: Diagnostic_studies / Prognostic_studies Limites: Aged / Animals / Female / Humans / Male / Middle aged Langue: En Journal: BMC Nephrol Sujet du journal: NEFROLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni